Cytokinetics (CYTK) 10.36 $CYTK Cytokinetics and Amgen

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 5:11 AM

Cytokinetics (CYTK) 10.36 $CYTK

Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016. Omecamtiv mecarbil, a novel investigational cardiac myosin activator, enhances cardiac function by increasing cardiac contractility and is being developed for the potential treatment of patients with chronic heart failure.
CYTK: 10.36 (-0.14), AMGN: 169.77 (-0.36)

Why You Shouldn't Bet Against Cytokinetics (CYTK) Stock
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:55AM CDT
Cytokinetics (CYTK) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
CYTK: 10.36 (-0.14)

Uptrend Call Working As Cytokinetics Stock Rises 61.5% (CYTK)
Comtex SmarTrend(R) - Fri Aug 26, 12:47PM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 5 months, Cytokinetics has returned 61.46% as of today's recent price of $12.15.
CYTK: 10.36 (-0.14)

Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:13AM CDT
Cytokinetics (CYTK) reported that it has completed patient enrollment in the phase III amyotrophic lateral sclerosis study on tirasemtiv.
CYTK: 10.36 (-0.14), AMGN: 169.77 (-0.36)

61.9% Return Seen to Date on SmarTrend Cytokinetics Call (CYTK)
Comtex SmarTrend(R) - Thu Aug 11, 12:46PM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 4 months, Cytokinetics has returned 61.86% as of today's recent price of $12.18.
CYTK: 10.36 (-0.14)

Cytokinetics (CYTK) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:28AM CDT
Cytokinetics, Incorporated (CYTK) has been on the move lately as the stock has risen by 19.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
CYTK: 10.36 (-0.14)

Cytokinetics Up 60.8% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Thu Aug 04, 12:19AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 4 months, Cytokinetics has returned 60.80% as of today's recent price of $12.10.
CYTK: 10.36 (-0.14)

Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 3:00PM CDT
Company Recently Announced Option Right for Tirasemtiv
CYTK: 10.36 (-0.14)

Cytokinetics Up 38.2% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Wed Jul 27, 1:22PM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 4 months, Cytokinetics has returned 38.21% as of today's recent price of $10.40.
CYTK: 10.36 (-0.14)

Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) and The ALS Association today announced the continuation and expansion of their partnership in the fight against ALS, including Cytokinetics' renewal of its Gold Level Sponsorship of the National Walks to Defeat ALS(R) and Platinum Level Sponsorship for initiatives led by The ALS Association Golden West Chapter.
CYTK: 10.36 (-0.14)

Cytokinetics Shares Up 19.9% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Fri Jun 17, 1:24AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 2 months, Cytokinetics has returned 19.87% as of today's recent price of $9.02.
CYTK: 10.36 (-0.14)

Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 3:05AM CDT
Cytokinetics, Incorporated (CYTK) saw its shares rise almost 7% in the last trading session.
CYTK: 10.36 (-0.14), ANIP: 59.86 (-1.56)

Cytokinetics to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue Jun 14, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the JMP Securities 2016 Life Sciences Conference on June 21, 2016 at 1:00 PM EDT at the St. Regis Hotel, New York, NY. Members of Cytokinetics' senior management team will also participate in the 3 Annual ROTH Healthcare Day on June 22, 2016 at The Dorchester Hotel in London, UK.
CYTK: 10.36 (-0.14)

Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
GlobeNewswire - Mon May 23, 6:30AM CDT
Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP
CYTK: 10.36 (-0.14), AMGN: 169.77 (-0.36)

Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 10.36 (-0.14), SRPT: 26.89 (+0.33)

Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
GlobeNewswire - Fri May 13, 3:00PM CDT
Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology, to be held May 21 - May 24, 2016 at the Fortezza da Basso in Florence, Italy.
CYTK: 10.36 (-0.14)

Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire - Wed May 11, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.
CYTK: 10.36 (-0.14)

Cytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month
GlobeNewswire - Mon May 02, 6:34AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company's commitment to education, awareness, research and development activities focused to amyotrophic lateral sclerosis (ALS). Cytokinetics' senior leadership team will be joined in this symbolic act by the leadership of the National, Golden West and New York Chapters of The ALS Association as well as people living with ALS and their loved ones.
CYTK: 10.36 (-0.14)

The ALS Association and Cytokinetics Ring in May as ALS Awareness Month at NASDAQ
PR Newswire - Sun May 01, 4:03PM CDT
May is ALS Awareness Month, an annual grassroots effort led by the ALS community and The ALS Association to raise awareness about amyotrophic lateral sclerosis (ALS) and move people to action in advancing the search for effective treatments and a cure. On Monday, May 2, The ALS Association is pleased to join Cytokinetics, Inc. (Nasdaq: CYTK), along with people living with ALS and their families, for the ringing of the closing bell at NASDAQ in New York City to kick off this year's campaign.
CYTK: 10.36 (-0.14)

Cytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Apr 29, 9:00AM CDT
What:
CYTK: 10.36 (-0.14), NDAQ: 71.67 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...